Drug Trial Radar · NCT05218499
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Mar 31, 2022
Primary completion
Apr 16, 2024
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate. The purpose of this study is to compare a medicine called brigimadlin (BI 907828) with doxorubicin in people with liposarcoma. Brigimadlin (BI 907828) is a so-called MDM2 inhibitor that is being developed to treat cancer. Doxorubicin is a medicine already used to treat cancer including liposarcoma. During the study, participants get either brigimadlin (BI 907828) or doxorubicin. Every 3 weeks, participants take brigimadlin (BI 907828) as tablets or doxorubicin as an infusion into a vein. Participants can switch to brigimadlin (BI 907828) treatment if they did not benefit from doxorubicin treatment. Participants can continue treatment in the study as long as they benefit from it and can tolerate it. Doctors regularly check the size of the tumour and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Liposarcoma, Dedifferentiated
Interventions
BrigimadlinDrug
Brigimadlin taken orally on day 1 of each 21-day cycle (q3w).
DoxorubicinDrug
Intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to 20.6 months.
Locations
109 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Arizona
Tucson, Arizona
Precision NextGen Oncology
Beverly Hills, California
City of Hope-Duarte-56419
Duarte, California
University of Southern California
Los Angeles, California
Sarcoma Oncology Center
Santa Monica, California
Mayo Clinic Cancer Center
Jacksonville, Florida
Winship Cancer Institute
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Mayo Clinic, Rochester
Rochester, Minnesota
Barnes-Jewish Hospital
St Louis, Missouri
Nebraska Cancer Specialists-Omaha-69502
Omaha, Nebraska
University Hospitals of Cleveland
Cleveland, Ohio
Oregon Health and Sciences University
Portland, Oregon
Henry-Joyce Cancer Clinic
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin
Prince of Wales Hospital-Randwick-66496
Randwick, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Ashford Cancer Centre Research
Kurralta Park, South Australia, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
UZ Leuven
Leuven, Belgium
BC Cancer Agency - Vancouver
Vancouver, British Columbia, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada
Cancer Hospital of Chinese Academy of Medical Science
Beijing, China
Beijing Cancer Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
West China Hospital, Sichuan University
Chengdu, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Zhongshan Hospital Affiliated to Fudan University
Shanghai, China
Wuhan Union Hospital
Wuhan, China
Masaryk Memorial Cancer Institute
Brno, Czechia
University Hospital Olomouc
Olomouc, Czechia
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.